Samsung Bio Entrusts Contract Development of Panoros Anticancer Drug Candidate

[Asia Economy Reporter Seo So-jeong] Samsung Biologics announced on the 17th that it has signed a contract for contract development (CDO) of the anticancer drug candidate 'PB101' with Panoros Bioscience.

Through this contract, Samsung Biologics plans to provide full CDO services for Panoros' 'PB101,' including cell line development, process development, clinical sample production, support for Investigational New Drug (IND) application submission, non-clinical and global clinical material production.

Panoros' next-generation anticancer drug candidate 'PB101' targets all isoforms of vascular endothelial growth factor (VEGF), which is excessively expressed around cancer cells, thereby inhibiting cancer cell growth. 'PB101' is a substance with a complex protein structure, making it highly challenging to research.

Im Hye-sung, CEO of Panoros, said, "'PB101' is expected to have excellent efficacy as an anticancer and VEGF-related disease treatment agent by itself, and moreover, the substance itself has already proven its value as a platform technology. We expect to achieve high synergy through close mutual cooperation with Samsung Biologics, which has global-level development capabilities, in the development of multi-target drug candidates including 'PB101' in the future."

Kim Tae-han, President of Samsung Biologics, said, "We are very pleased to establish a partnership with Panoros, which has outstanding potential in the field of protein drug development. We will do our best to accelerate the development of client substances through the world-class CDO services we provide."

This content was produced with the assistance of AI translation services.